Mavorixafor

115 interactions 9 explained in plain English
Also sold as: Xolremdi
Dr. Brian Staiger, PharmD, BCPS
Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Jul 4, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Acetaminophen And Codeine Deutetrabenazine Gefitinib Flecainide Metoclopramide Nasal Spray Aripiprazole Injection
14 Contraindicated 99 Major 2 Moderate
All (115) Contraindicated (14) Major (99) Moderate (2)

Contraindicated

Mavorixafor Acetaminophen And Codeine Capital® & Codeine Explained Increased CYP2D6 substrate exposure and an increased risk of CYP2D6 substrate-related adverse events Details Mavorixafor Amitriptyline Elavil Explained Increased CYP2D6 substrate exposure, increased risk of CYP2D6-related adverse events and an increased risk of QT interval prolonga... Details Mavorixafor Aripiprazole Injection Abilify Increased CYP2D6 substrate exposure, increased risk of CYP2D6-related adverse events and an increased risk of QT interval prolonga... Details Mavorixafor Brexpiprazole Rexulti Increased CYP2D6 substrate exposure and an increased risk of CYP2D6 substrate-related adverse events Details Mavorixafor Deutetrabenazine Austedo Increased CYP2D6 substrate exposure, increased risk of CYP2D6-related adverse events and an increased risk of QT interval prolonga... Details Mavorixafor Doxorubicin Adriamycin Increased CYP2D6 substrate exposure and an increased risk of CYP2D6 substrate-related adverse events Details Mavorixafor Flecainide Tambocor® Increased CYP2D6 substrate exposure, increased risk of CYP2D6-related adverse events and an increased risk of QT interval prolonga... Details Mavorixafor Gefitinib Iressa Increased CYP2D6 substrate exposure and an increased risk of CYP2D6 substrate-related adverse events Details Mavorixafor Loratadine Agistam® Increased CYP2D6 substrate exposure and an increased risk of CYP2D6 substrate-related adverse events Details Mavorixafor Maprotiline Ludiomil® Increased CYP2D6 substrate exposure and an increased risk of CYP2D6 substrate-related adverse events Details Mavorixafor Metoclopramide Injection Gimoti Increased CYP2D6 substrate exposure and an increased risk of CYP2D6 substrate-related adverse events Details Mavorixafor Metoclopramide Nasal Spray Gimoti Increased CYP2D6 substrate exposure and an increased risk of CYP2D6 substrate-related adverse events Details Mavorixafor Mexiletine Mexitil® Increased CYP2D6 substrate exposure and an increased risk of CYP2D6 substrate-related adverse events Details Mavorixafor Nebivolol Bystolic Increased CYP2D6 substrate exposure and an increased risk of CYP2D6 substrate-related adverse events Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist
Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.